This is a process measure of the annual proportion of eligible patients ≥ 18 years of age, who were prescribed aspirin, P2Y12 inhibitor, and statin at discharge following PCI with or without stenting.
30-Day Unplanned Readmissions for Cancer Patients measure is a cancer-specific measure. It provides the rate at which adult cancer patients have an unplanned readmission within 30 days of discharge from an acute care hospital. The unplanned readmission is defined as a subsequent inpatient admission to a short-term acute care hospital, which occurs within 30 days of the discharge date of an eligible index admission and has an admission type of “emergency” or “urgent.”
Percentage of individuals at least 18 years of age as of the beginning of the performance period with schizophrenia or schizoaffective disorder who had at least two prescriptions filled for any antipsychotic medication and who had a Proportion of Days Covered (PDC) of at least 0.8 for antipsychotic medications during the performance period.
The Consumer Assessment of Healthcare Providers and Systems (CAHPS) Clinician & Group Survey 3.1 (CG-CAHPS) is a standardized survey instrument that asks patients to report on their experiences with primary or specialty care received from providers and their staff in ambulatory care settings over the preceding 6 months. CG-CAHPS Survey Version 1.0 was endorsed by NQF in July 2007 (NQF #0005) and version 2.0 received maintenance endorsement in early 2015. Version 3.0 was released in July 2015 and was last endorsed in 2019.
The CAHPS Health Plan (HP CAHPS) Survey is a survey that asks health plan enrollees to report about their care and health plan experiences as well as the quality of care received from physicians. HP CAHPS Version 4.0 was endorsed by NQF in July 2007, and Version 5.0 received maintenance endorsement in January 2015 and was last endorsed in Spring 2019 (CBE #0006). The 5.1 version of the CAHPS Health Plan Survey, released in the fall of 2020, explicitly asks about respondents’ experiences with care received in person, by phone, and by video to account for changes in care due to the pandemic.
The CAHPS Health Plan (HP CAHPS) Survey is a survey that asks health plan enrollees to report about their care and health plan experiences as well as the quality of care received from physicians. HP CAHPS Version 4.0 was endorsed by NQF in July 2007, and Version 5.0 received maintenance endorsement in January 2015 and was last endorsed in Spring 2019 (CBE #0006). The 5.1 version of the CAHPS Health Plan Survey, released in the fall of 2020, explicitly asks about respondents’ experiences with care received in person, by phone, and by video to account for changes in care due to the pandemic.
The CAHPS Health Plan (HP CAHPS) Survey is a survey that asks health plan enrollees to report about their care and health plan experiences as well as the quality of care received from physicians. HP CAHPS Version 4.0 was endorsed by NQF in July 2007, and Version 5.0 received maintenance endorsement in January 2015 and was last endorsed in Spring 2019 (CBE #0006). The 5.1 version of the CAHPS Health Plan Survey, released in the fall of 2020, explicitly asks about respondents’ experiences with care received in person, by phone, and by video to account for changes in care due to the pandemic.
The CAHPS Health Plan (HP CAHPS) Survey is a survey that asks health plan enrollees to report about their care and health plan experiences as well as the quality of care received from physicians. HP CAHPS Version 4.0 was endorsed by NQF in July 2007, and Version 5.0 received maintenance endorsement in January 2015 and was last endorsed in Spring 2019 (CBE #0006). The 5.1 version of the CAHPS Health Plan Survey, released in the fall of 2020, explicitly asks about respondents’ experiences with care received in person, by phone, and by video to account for changes in care due to the pandemic.
Percentage of patients aged 18 years and older with a diagnosis of chronic kidney disease (CKD) (Stages 1-5, not receiving Renal Replacement Therapy (RRT)) and proteinuria who were prescribed ACE inhibitor or ARB therapy within a 12-month period.
This measure is NQF Measure 1662/MIPS Measure 489.
This measure calculates the authorization rate for organ donation (defined as authorizations per 100 approaches) among referred potential organ donors or their next of kin within the Organ Procurement Organization’s (OPO’s) donation service area (DSA) in a calendar year.